Feb 16, 2016 13:00 pm UTC| Business
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 16, 2016 -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative...
iAPPS Listed in Info-Tech Research Group’s WEM Vendor Landscape
Feb 16, 2016 13:00 pm UTC| Business
BURLINGTON, Mass., Feb. 16, 2016 -- Bridgeline Digital, Inc. (NASDAQ:BLIN), The Digital Engagement Company™, announced today that the iAPPS Digital Marketing Platform was listed in Info-Tech Research Group’s recent...
Intra-Cellular Therapies to Present at the 2016 RBC Capital Markets’ Healthcare Conference
Feb 16, 2016 13:00 pm UTC| Business
NEW YORK, Feb. 16, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon...
Erickson to Construct Transmission Towers for Sterlite Grid in the Pir Panjal Range of India
Feb 16, 2016 13:00 pm UTC| Business
PORTLAND, Ore., Feb. 16, 2016 -- Erickson Incorporated (NASDAQ:EAC), a leading global provider of aviation services, is partnering with Sterlite Grid to install nearly 160 power transmission towers in the challenging...
Inventure Foods to Report Fourth Quarter and Fiscal Year 2015 Financial Results
Feb 16, 2016 13:00 pm UTC| Business
PHOENIX, Feb. 16, 2016 -- Inventure Foods, Inc. (Nasdaq:SNAK), a leading specialty food marketer and manufacturer, today announced that it will release financial results for the fourth quarter and fiscal year ended...
Freshpet, Inc. to Report Fourth Quarter and Fiscal 2015 Results on Wednesday, March 9, 2016
Feb 16, 2016 13:00 pm UTC| Business
SEACAUCUS, N.J., Feb. 16, 2016 -- Freshpet, Inc. (NASDAQ:FRPT) (“Freshpet” or the “Company”) today announced it will report results for the fourth quarter and fiscal year ended December 31, 2015 on Wednesday, March 9,...
Feb 16, 2016 13:00 pm UTC| Business
BOTHELL, Wash., Feb. 16, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Cushing's disease,...